|1.||Newman-Tancredi, Adrian: 4 articles (11/2008 - 08/2005)|
|2.||Barret-Grévoz, Catherine: 3 articles (11/2008 - 08/2005)|
|3.||Bardin, Laurent: 3 articles (11/2008 - 09/2006)|
|4.||Depoortère, Ronan: 2 articles (11/2008 - 09/2006)|
|5.||Kleven, Mark S: 2 articles (09/2006 - 08/2005)|
|6.||Huang, Xu-Feng: 1 article (09/2014)|
|7.||De Santis, Michael: 1 article (09/2014)|
|8.||Deng, Chao: 1 article (09/2014)|
|9.||Lian, Jiamei: 1 article (09/2014)|
|10.||Pan, Bo: 1 article (09/2014)|
|1.||Schizophrenia (Dementia Praecox)
10/01/2008 - "The current study evaluated the efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia. "
10/01/2008 - "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study."
03/01/2009 - "Thus, bifeprunox would be expected to be an effective compound against positive and negative symptoms of schizophrenia."
10/01/2008 - "These data suggest that 20 mg of bifeprunox may be efficacious in improving symptoms in patients with an acute exacerbation of schizophrenia. "
01/01/2003 - "DU-127090 is a mixed dopamine antagonist/serotonin agonist in development by Solvay and H Lundbeck as a potential treatment for psychosis and schizophrenia, for which it is in phase II clinical trials. "
|2.||Body Weight (Weight, Body)
09/01/2014 - "This study has therefore investigated the different effects of 10 week treatment with Aripiprazole (0.75 mg/kg, 3 times per day), Bifeprunox (0.8 mg/kg, 3 times per day) and Haloperidol (0.1mg/kg, 3 times per day) on body weight gain, food and water intake, white fat mass, and 8 week treatment on locomotor activity. "
09/01/2014 - "Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats."
08/01/2005 - "In contrast, SSR181507 and bifeprunox potently inhibited both CLP and bar catalepsy. "
09/01/2006 - "When 5-HT1A receptors were blocked by pretreatment with WAY100635 (2.5 mg/kg, s.c.), cataleptogenic properties of SSR181507 and sarizotan were unmasked, and the catalepsy induced by bifeprunox was enhanced. "
08/01/2005 - "However, when 5-HT(1A) receptors were blocked with the selective antagonist, WAY100635 (0.63 mg/kg, SC), robust cataleptogenic properties of SLV313, bifeprunox and sarizotan were unmasked and the catalepsy induced by ziprasidone was accentuated. "
08/01/2005 - "When administered alone, ziprasidone produced marked catalepsy, whereas aripiprazole, bifeprunox, SLV313, SSR181507 and sarizotan did not. "
|4.||Weight Loss (Weight Reduction)
|3.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)
|5.||(3- exo)- 8- benzoyl- N- (((2S)7- chloro- 2,3- dihydro- 1,4- benzodioxin- 1- yl)methyl)- 8- azabicyclo(3.2.1)octane- 3- methanamine monohydrochloride
|6.||1- (2,3- dihydro- 1,4- benzodioxin- 5- yl)- 4- ((5- (4- fluorophenyl)- 3- pyridinyl)methyl)piperazine
|9.||Valproic Acid (Valproate, Semisodium)